NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

Market opportunities for mRNA synthesis raw materials lie in the growing demand for high-purity materials driven by mRNA therapeutics. Key drivers include advancements in mRNA technology, regulatory ...

The Department of Health and Human Services announced Thursday that it will cut nearly half a billion dollars in funding for 22 vaccine development programs, many of which ...